divisun 800 ie
viatris as - kolekalsiferol - tablett - 800 ie
divisun 2000 ie
viatris as - kolekalsiferol - tablett - 2000 ie
divisun 4000 ie
viatris as - kolekalsiferol - tablett - 4000 ie
holoxan 2000 mg
baxter medical ab - ifosfamid - pulver til injeksjons-/infusjonsvæske, oppløsning - 2000 mg
holoxan 500 mg
baxter medical ab - ifosfamid - pulver til injeksjons-/infusjonsvæske, oppløsning - 500 mg
holoxan 1000 mg
baxter medical ab - ifosfamid - pulver til injeksjons-/infusjonsvæske, oppløsning - 1000 mg
magnesiumsulfat b. braun 1 mmol/ ml
b. braun melsungen ag - magnesiumsulfatheptahydrat - konsentrat til infusjonsvæske, oppløsning - 1 mmol/ ml
divifarm 800 iu
orifarm generics a/s - kolekalsiferol - tablett, filmdrasjert - 800 iu
colecalciferol eql pharma 2000 ie
eql pharma ab - kolekalsiferol - tablett - 2000 ie
faslodex
astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.